Skip to main content

Advertisement

Table 2 Network meta-analysis of efficacy and safety outcomes of new antidiabetic drug classes using random-effects model

From: Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis

MACE
 GLP-1 RA 1.01 (0.92–1.12) 1.14 (1.04–1.26) 1.14 (1.07–1.22)
 0.99 (0.89–1.09) SGLT-2 inhibitor 1.13 (1.02–1.25) 1.13 (1.05–1.22)
 0.88 (0.80–0.96) 0.89 (0.80–0.98) DPP-4 inhibitor 1.00 (0.94–1.07)
 0.87 (0.82–0.93) 0.88 (0.82–0.95) 1.00 (0.93–1.07) Placebo
Nonfatal myocardial infarction
 GLP-1 RA 1.04 (0.88–1.23) 1.13 (0.97–1.32) 1.11 (1.00–1.24)
 0.96 (0.81–1.13) SGLT-2 inhibitor 1.08 (0.91–1.29) 1.07 (0.94–1.22)
 0.88 (0.78–1.04) 0.92 (0.77–1.10) DPP-4 inhibitor 0.98 (0.88–1.11)
 0.90 (0.81–1.00) 0.94 (0.82–1.07) 1.02 (0.90–1.14) Placebo
Nonfatal stroke
 GLP-1 RA 1.17 (0.98–1.41) 1.12 (0.93–1.35) 1.14 (1.01–1.29)
 0.85 (0.71–1.02) SGLT-2 inhibitor 0.95 (0.79–1.16) 0.97 (0.85–1.11)
 0.89 (0.74–1.08) 1.05 (0.87–1.27) DPP-4 inhibitor 1.02 (0.89–1.18)
 0.88 (0.77–0.99) 1.03 (0.90–1.17) 0.98 (0.85–1.13) Placebo
Cardiovascular mortality
 GLP-1 RA 0.93 (0.78–1.11) 1.11 (0.93–1.33) 1.13 (0.99–1.28)
 1.08 (0.90–1.29) SGLT-2 inhibitor 1.20 (1.01–1.42) 1.22 (1.08–1.38)
 0.90 (0.75–1.07) 0.83 (0.70–0.99) DPP-4 inhibitor 1.02 (0.90–1.15)
 0.89 (0.78–1.01) 0.82 (0.73–0.93) 0.98 (0.87–1.11) Placebo
All-cause mortality
 GLP-1 RA 0.93 (0.82–1.06) 1.13 (0.99–1.28) 1.11 (1.02–1.22)
 1.07 (0.94–1.22) SGLT-2 inhibitor 1.20 (1.06–1.37) 1.19 (1.09–1.30)
 0.89 (0.78–1.01) 0.83 (0.73–0.94) DPP-4 inhibitor 0.99 (0.91–1.08)
 0.90 (0.82–0.99) 0.84 (0.77–0.92) 1.01 (0.93–1.10) Placebo
Hospitalisation for heart failure
 GLP-1 RA 0.79 (0.69–0.90) 1.22 (1.08–1.37) 1.15 (1.08–1.22)
 1.27 (1.11–1.45) SGLT-2 inhibitor 1.55 (1.33–1.81) 1.46 (1.30–1.64)
 0.82 (0.73–0.92) 0.64 (0.55–0.75) DPP-4 inhibitor 0.94 (0.85–1.04)
 0.87 (0.82–0.93) 0.68 (0.61–0.77) 1.06 (0.96–1.18) Placebo
Renal composite outcome
 GLP-1 RA 0.69 (0.59–0.80) 1.16 (1.03–1.31) 1.16 (1.06–1.27)
 1.46 (1.25–1.70) SGLT-2 inhibitor 1.69 (1.46–1.96) 1.70 (1.50–1.91)
 0.86 (0.76–0.98) 0.59 (0.51–0.69) DPP-4 inhibitor 1.00 (0.92–1.09)
 0.86 (0.78–0.94) 0.59 (0.52–0.67) 1.00 (0.92–1.08) Placebo
  1. DPP-4: dipeptidyl peptidase-4; GLP-1: glucagon-like peptide-1; MACE: major adverse cardiovascular events (defined as the composite of cardiovascular mortality, nonfatal myocardial infarction and nonfatal stroke); RA: receptor agonist; SGLT-2: sodium-glucose co-transporter 2
  2. Comparisons should be read from left to right. Results are the odds ratios (95% confidence interval) in the column-defining therapy compared with the odds ratios in the row-defining therapy. For efficacy and safety, odds ratio < 1 favours the column-defining therapy. Significant results are shown in italic